1. Home
  2. NGNE vs RPAY Comparison

NGNE vs RPAY Comparison

Compare NGNE & RPAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$20.61

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Logo Repay Holdings Corporation

RPAY

Repay Holdings Corporation

HOLD

Current Price

$3.69

Market Cap

364.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
RPAY
Founded
2003
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
327.8M
364.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NGNE
RPAY
Price
$20.61
$3.69
Analyst Decision
Strong Buy
Buy
Analyst Count
6
9
Target Price
$38.50
$6.81
AVG Volume (30 Days)
188.3K
1.3M
Earning Date
11-13-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$308,947,000.00
Revenue This Year
N/A
$0.22
Revenue Next Year
N/A
$6.91
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.88
$2.98
52 Week High
$37.27
$7.86

Technical Indicators

Market Signals
Indicator
NGNE
RPAY
Relative Strength Index (RSI) 47.11 50.72
Support Level $19.28 $3.61
Resistance Level $22.99 $3.99
Average True Range (ATR) 1.44 0.16
MACD 0.32 0.02
Stochastic Oscillator 40.15 54.07

Price Performance

Historical Comparison
NGNE
RPAY

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About RPAY Repay Holdings Corporation

Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments.

Share on Social Networks: